Stroke, 10 March 2015 Stroke remains the third leading cause of death in women affecting 3.8 million women compared with 3 million men. Almost half of the women surviving stroke are anticipated to have residual deficits, including cognitive dysfunction and weakness 6 months later. With the aging population and increased longevity of women in our […]
Stroke, 16 July 2015 Background and Purpose—The National Institutes of Health policy calls for the inclusion of under-represented groups, such as women and minorities, in clinical research. Poor minority recruitment and retention in stroke clinical trials remain a significant challenge limiting safety and efficacy in a general population. Previous research examines participant barriers to clinical […]
Stroke, 18 June 2015 Background and Purpose—The majority of genome-wide association studies (GWAS) of stroke have focused on European-ancestry populations; however, none has been conducted in African Americans, despite the disproportionately high burden of stroke in this population. The Consortium of Minority Population Genome-Wide Association Studies of Stroke (COMPASS) was established to identify stroke susceptibility […]
Stroke, 6 August 2015 Background and Purpose—A substantial part of ischemic strokes is attributed to atrial fibrillation (AF). We hypothesized that patients with ischemic stroke without prior diagnosed AF were at higher risk of having a subsequent diagnosis of AF, and this was associated with multiple risk factors.… Conclusions—Ischemic stroke was associated with a substantially […]
Stroke, 30 July 2015 Background and Purpose—The use of vitamin K antagonists (VKAs), the cornerstone treatment for stroke prevention in patients with atrial fibrillation, is limited by the perceived risk of serious bleeding in Asia. Non-VKA oral anticoagulants (NOACs) are safer alternatives. Here, we evaluate performance differences of NOACs between Asians and non-Asians.… Conclusions—Our findings […]
JAMA, 21 July 2015 Importance Atrial fibrillation is a common arrhythmia that affects more than 2.5 million people in the United States and causes substantial morbidity and mortality, especially regarding the increased risk of stroke. Objective To summarize atrial fibrillation treatment exclusive of stroke prevention.… Conclusions and Relevance Therapy for atrial fibrillation includes prevention and modification of inciting […]
J Am Heart Assoc, 17 July 2015 Background The quality of antithrombotic therapy for patients with nonvalvular atrial fibrillation during routine medical care is often suboptimal. Evidence linking stroke and bleeding risk with antithrombotic treatment is limited. The purpose of this study was to evaluate the associations between antithrombotic treatment episodes and outcomes.… Conclusions Continuation […]
HeartRhythm, July 2015 Background Atrial fibrillation (AF) is associated with an increased risk of stroke and death. Uniform utilization of appropriate therapies for AF may help reduce those risks. Objective We sought to determine whether significant race and sex differences exist in the treatment of newly diagnosed AF in Medicare beneficiaries.… Conclusion Race and sex […]
Stroke, 9 July 2015 Background and Purpose—It is unknown whether women and men with acute ischemic stroke respond similar to an antioxidant regimen administered in combination with thrombolysis. Here, we investigated the independent effect of sex on the response to uric acid (UA) therapy in patients with acute stroke treated with alteplase.… Conclusions—In women with […]
Stroke, 7 July 2015 Background and Purpose—We developed a new postdischarge system of care comprising a structured assessment covering longer-term problems experienced by patients with stroke and their carers, linked to evidence-based treatment algorithms and reference guides (the longer-term stroke care system of care) to address the poor longer-term recovery experienced by many patients with […]
